NASDAQ:APYXApyx Medical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apyx Medical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.00 +0.02 (+0.40 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$4.85Now: $5.00▼$5.0250-Day Range$4.49MA: $5.09▼$5.6952-Week Range$2.81Now: $5.00▼$8.59Volume46,801 shsAverage Volume108,973 shsMarket Capitalization$170.92 millionP/E RatioN/ADividend YieldN/ABeta0.71 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingApyx Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Apyx Medical has a potential upside of 46.7% from its current price of $5.00.Amount of Analyst CoverageApyx Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesApyx Medical has received 48 “outperform” votes. (Add your “outperform” vote.)Underperform VotesApyx Medical has received 46 “underperform” votes. (Add your “underperform” vote.)Community SentimentApyx Medical has received 51.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Apyx Medical and other stocks. Vote “Outperform” if you believe APYX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APYX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldApyx Medical does not currently pay a dividend.Dividend GrowthApyx Medical does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apyx Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $93,225.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Apyx Medical is held by insiders.Percentage Held by Institutions51.78% of the stock of Apyx Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Apyx Medical are expected to decrease in the coming year, from ($0.68) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apyx Medical is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apyx Medical is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApyx Medical has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.02 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APYX Previous Symbol CUSIPN/A CIKN/A Webwww.apyxmedical.com Phone727-384-2323Debt Debt-to-Equity Ratio0.01 Current Ratio7.00 Quick Ratio6.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$28.15 million Price / Sales6.07 Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book2.39Profitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-19,710,000.00 Net Margins-58.26% Return on Equity-21.45% Return on Assets-18.72%Miscellaneous Employees222 Outstanding Shares34,184,000Market Cap$170.92 million Next Earnings Date8/10/2020 (Confirmed) OptionableOptionable $5.00 +0.02 (+0.40 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive APYX News and Ratings via Email Sign-up to receive the latest news and ratings for APYX and its competitors with MarketBeat's FREE daily newsletter. Apyx Medical (NASDAQ:APYX) Frequently Asked Questions How has Apyx Medical's stock been impacted by COVID-19 (Coronavirus)? Apyx Medical's stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APYX stock has decreased by 1.2% and is now trading at $5.00. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Apyx Medical? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Apyx Medical. When is Apyx Medical's next earnings date? Apyx Medical is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Apyx Medical. How can I listen to Apyx Medical's earnings call? Apyx Medical will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Apyx Medical's earnings last quarter? Apyx Medical Corp (NASDAQ:APYX) released its earnings results on Monday, May, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.05. The business had revenue of $5 million for the quarter, compared to analyst estimates of $5.29 million. Apyx Medical had a negative net margin of 58.26% and a negative return on equity of 21.45%. View Apyx Medical's earnings history. What price target have analysts set for APYX? 2 brokers have issued 12 month target prices for Apyx Medical's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Apyx Medical's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 46.7% from the stock's current price. View analysts' price targets for Apyx Medical. Has Apyx Medical been receiving favorable news coverage? Media headlines about APYX stock have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Apyx Medical earned a news impact score of -1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Apyx Medical. Are investors shorting Apyx Medical? Apyx Medical saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 603,700 shares, an increase of 6.4% from the July 15th total of 567,300 shares. Based on an average daily volume of 130,200 shares, the short-interest ratio is presently 4.6 days. Approximately 2.0% of the shares of the stock are short sold. View Apyx Medical's Current Options Chain. Who are some of Apyx Medical's key competitors? Some companies that are related to Apyx Medical include Intersect ENT (XENT), SurModics (SRDX), Orthofix Medical (OFIX), MiMedx Group (MDXG), Invo Bioscience (IVOB), LeMaitre Vascular (LMAT), SI-Bone (SIBN), Antares Pharma (ATRS), Anika Therapeutics (ANIK), Alphatec (ATEC), Cytosorbents (CTSO), SeaSpine (SPNE), Repro Med Systems (KRMD), Repro-Med Systems (REPR) and AngioDynamics (ANGO). View all competitors. What other stocks do shareholders of Apyx Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), Procter & Gamble (PG), AT&T (T), Wells Fargo & Co (WFC), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Bank of America (BAC) and Corbus Pharmaceuticals (CRBP). Who are Apyx Medical's key executives? Apyx Medical's management team includes the following people: Mr. Charles D. Goodwin II, Pres, CEO & Director (Age 53)Ms. Tara H. Semb, CFO, Treasurer & Sec. (Age 49)Mr. Moshe Citronowicz, Sr. VP (Age 66)Mr. Todd Hornsby, Exec. VP (Age 43) What is Apyx Medical's stock symbol? Apyx Medical trades on the NASDAQ under the ticker symbol "APYX." Who are Apyx Medical's major shareholders? Apyx Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (1.63%), Raymond James Financial Services Advisors Inc. (0.80%), Cowen Prime Services LLC (0.70%), ProVise Management Group LLC (0.50%), Creative Financial Designs Inc. ADV (0.08%) and SG Americas Securities LLC (0.05%). View institutional ownership trends for Apyx Medical. Which institutional investors are selling Apyx Medical stock? APYX stock was sold by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Creative Financial Designs Inc. ADV, and ProVise Management Group LLC. View insider buying and selling activity for Apyx Medical. Which institutional investors are buying Apyx Medical stock? APYX stock was bought by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Raymond James Financial Services Advisors Inc., and SG Americas Securities LLC. View insider buying and selling activity for Apyx Medical. How do I buy shares of Apyx Medical? Shares of APYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Apyx Medical's stock price today? One share of APYX stock can currently be purchased for approximately $5.00. How big of a company is Apyx Medical? Apyx Medical has a market capitalization of $170.92 million and generates $28.15 million in revenue each year. The company earns $-19,710,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Apyx Medical employs 222 workers across the globe. What is Apyx Medical's official website? The official website for Apyx Medical is www.apyxmedical.com. How can I contact Apyx Medical? Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The company can be reached via phone at 727-384-2323 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
